BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Stock Fundamental Analysis

BIT:1BMRN • US09061G1013

48.12 EUR
-2.58 (-5.09%)
Last: Jan 23, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

Taking everything into account, 1BMRN scores 6 out of 10 in our fundamental rating. 1BMRN was compared to 78 industry peers in the Biotechnology industry. 1BMRN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. 1BMRN may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make 1BMRN a good candidate for value and quality investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • 1BMRN had positive earnings in the past year.
  • In the past year 1BMRN had a positive cash flow from operations.
  • 1BMRN had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years 1BMRN had a positive operating cash flow.
1BMRN.MI Yearly Net Income VS EBIT VS OCF VS FCF1BMRN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

  • 1BMRN has a better Return On Assets (6.83%) than 82.35% of its industry peers.
  • 1BMRN has a better Return On Equity (8.59%) than 80.00% of its industry peers.
  • 1BMRN has a better Return On Invested Capital (7.69%) than 84.71% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for 1BMRN is significantly below the industry average of 11.39%.
  • The last Return On Invested Capital (7.69%) for 1BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.83%
ROE 8.59%
ROIC 7.69%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1BMRN.MI Yearly ROA, ROE, ROIC1BMRN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

  • With an excellent Profit Margin value of 16.82%, 1BMRN belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
  • 1BMRN has a better Operating Margin (20.21%) than 83.53% of its industry peers.
  • 1BMRN's Gross Margin of 81.32% is fine compared to the rest of the industry. 1BMRN outperforms 70.59% of its industry peers.
  • 1BMRN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.21%
PM (TTM) 16.82%
GM 81.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
1BMRN.MI Yearly Profit, Operating, Gross Margins1BMRN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so 1BMRN is destroying value.
  • 1BMRN has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, 1BMRN has more shares outstanding
  • 1BMRN has a better debt/assets ratio than last year.
1BMRN.MI Yearly Shares Outstanding1BMRN.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
1BMRN.MI Yearly Total Debt VS Total Assets1BMRN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • 1BMRN has an Altman-Z score of 5.44. This indicates that 1BMRN is financially healthy and has little risk of bankruptcy at the moment.
  • 1BMRN has a Altman-Z score of 5.44. This is in the better half of the industry: 1BMRN outperforms 78.82% of its industry peers.
  • 1BMRN has a debt to FCF ratio of 0.72. This is a very positive value and a sign of high solvency as it would only need 0.72 years to pay back of all of its debts.
  • 1BMRN has a Debt to FCF ratio of 0.72. This is amongst the best in the industry. 1BMRN outperforms 85.88% of its industry peers.
  • 1BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
  • 1BMRN's Debt to Equity ratio of 0.10 is fine compared to the rest of the industry. 1BMRN outperforms 63.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.72
Altman-Z 5.44
ROIC/WACC0.92
WACC8.4%
1BMRN.MI Yearly LT Debt VS Equity VS FCF1BMRN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

  • A Current Ratio of 4.83 indicates that 1BMRN has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 4.83, 1BMRN is doing good in the industry, outperforming 78.82% of the companies in the same industry.
  • A Quick Ratio of 3.10 indicates that 1BMRN has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 3.10, 1BMRN is doing good in the industry, outperforming 68.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.83
Quick Ratio 3.1
1BMRN.MI Yearly Current Assets VS Current Liabilites1BMRN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 52.00% over the past year.
  • Looking at the last year, 1BMRN shows a quite strong growth in Revenue. The Revenue has grown by 12.39% in the last year.
  • 1BMRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.86% yearly.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%

3.2 Future

  • Based on estimates for the next years, 1BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.19% on average per year.
  • The Revenue is expected to grow by 7.22% on average over the next years.
EPS Next Y28.21%
EPS Next 2Y44.96%
EPS Next 3Y35.45%
EPS Next 5Y28.19%
Revenue Next Year12.62%
Revenue Next 2Y11.16%
Revenue Next 3Y10.75%
Revenue Next 5Y7.22%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1BMRN.MI Yearly Revenue VS Estimates1BMRN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
1BMRN.MI Yearly EPS VS Estimates1BMRN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 21.58 indicates a rather expensive valuation of 1BMRN.
  • Based on the Price/Earnings ratio, 1BMRN is valued cheaper than 84.71% of the companies in the same industry.
  • 1BMRN is valuated rather cheaply when we compare the Price/Earnings ratio to 26.99, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 12.35, 1BMRN is valued correctly.
  • 1BMRN's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1BMRN is cheaper than 95.29% of the companies in the same industry.
  • 1BMRN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.06.
Industry RankSector Rank
PE 21.58
Fwd PE 12.35
1BMRN.MI Price Earnings VS Forward Price Earnings1BMRN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1BMRN indicates a rather cheap valuation: 1BMRN is cheaper than 83.53% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1BMRN indicates a rather cheap valuation: 1BMRN is cheaper than 94.12% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 13.34
EV/EBITDA 14
1BMRN.MI Per share data1BMRN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • 1BMRN has a very decent profitability rating, which may justify a higher PE ratio.
  • 1BMRN's earnings are expected to grow with 35.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.76
PEG (5Y)N/A
EPS Next 2Y44.96%
EPS Next 3Y35.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for 1BMRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOMARIN PHARMACEUTICAL INC

BIT:1BMRN (1/23/2026, 7:00:00 PM)

48.12

-2.58 (-5.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27
Earnings (Next)02-25
Inst Owners97.82%
Inst Owner ChangeN/A
Ins Owners0.64%
Ins Owner ChangeN/A
Market Cap9.24B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.88
Price Target80.11 (66.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)-2.74%
PT rev (3m)-2.74%
EPS NQ rev (1m)-29.03%
EPS NQ rev (3m)-24.43%
EPS NY rev (1m)-5.52%
EPS NY rev (3m)-16.53%
Revenue NQ rev (1m)0.68%
Revenue NQ rev (3m)0.77%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.12%
Valuation
Industry RankSector Rank
PE 21.58
Fwd PE 12.35
P/S 3.56
P/FCF 13.34
P/OCF 12.06
P/B 1.82
P/tB 1.96
EV/EBITDA 14
EPS(TTM)2.23
EY4.63%
EPS(NY)3.9
Fwd EY8.1%
FCF(TTM)3.61
FCFY7.49%
OCF(TTM)3.99
OCFY8.3%
SpS13.51
BVpS26.45
TBVpS24.58
PEG (NY)0.76
PEG (5Y)N/A
Graham Number36.43
Profitability
Industry RankSector Rank
ROA 6.83%
ROE 8.59%
ROCE 9.17%
ROIC 7.69%
ROICexc 9.82%
ROICexgc 10.68%
OM 20.21%
PM (TTM) 16.82%
GM 81.32%
FCFM 26.69%
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.72
Debt/EBITDA 0.84
Cap/Depr 106.6%
Cap/Sales 2.85%
Interest Coverage 85.91
Cash Conversion 129.08%
Profit Quality 158.68%
Current Ratio 4.83
Quick Ratio 3.1
Altman-Z 5.44
F-Score8
WACC8.4%
ROIC/WACC0.92
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y28.21%
EPS Next 2Y44.96%
EPS Next 3Y35.45%
EPS Next 5Y28.19%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.62%
Revenue Next 2Y11.16%
Revenue Next 3Y10.75%
Revenue Next 5Y7.22%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.1%
EBIT Next 3Y41.17%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%

BIOMARIN PHARMACEUTICAL INC / 1BMRN.MI FAQ

Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?

ChartMill assigns a fundamental rating of 6 / 10 to 1BMRN.MI.


What is the valuation status for 1BMRN stock?

ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (1BMRN.MI). This can be considered as Undervalued.


What is the profitability of 1BMRN stock?

BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for 1BMRN stock?

The Price/Earnings (PE) ratio for BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) is 21.58 and the Price/Book (PB) ratio is 1.82.